-
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
28 Apr 2025 20:10 GMT
… ) in September 2024 and UK Medicines and Healthcare products Regulatory Agency (MHRA … . Elafibranor was developed by GENFIT. Ipsen licensed the exclusive worldwide rights … , Europe and worldwide, of our drug and diagnostic candidates, pricing, approval …
-
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
28 Apr 2025 20:10 GMT
… #39;hui qu'Ipsen présentera les données positives de … . GENFIT a licencié à Ipsen les droits exclusifs mondiaux ( … and Drug Administration (FDA) américaine ou l’Agence Européenne des médicaments … commercialisé aux Etats-Unis par Ipsen sous la marque Iqirvo® …
-
Ipsen to present elafibranor data from phase II ELMWOOD clinical study at EASL Congress 2025 on May 10, 2025
28 Apr 2025 13:01 GMT
Ipsen, will be presenting data from … head of R&D, Ipsen. “These results are encouraging and … of Miami Miller School of Medicine, Miami, Florida. “Primary sclerosing … Elafibranor was developed by GENFIT. Ipsen licensed the exclusive worldwide rights …
-
Liver Lineup: Updates & Unfiltered Insights
01 May 2025 10:20 GMT
… and hepatology and the Associate Medical Director of the Henry Ford … of Hepatology at Rush University Medical Center.
In the inaugural episode … disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.
-
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
29 Apr 2025 19:10 GMT
… life-threatening liver diseases whose medical needs remain largely unmet. GENFIT … Euronext: GNFT). In 2021, Ipsen became one of GENFIT… Europe and worldwide, of our drug and diagnostic candidates, pricing, … in the U.S by Ipsen under the trademark Iqirvo®. …
-
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du Rapport Annuel Form 20-F 2024
29 Apr 2025 19:10 GMT
… vital, dont les besoins médicaux restent largement insatisfaits. GENFIT … : GNFT). En 2021, Ipsen est devenu l’un des … niveau mondial concernant les candidats-médicaments et solutions diagnostiques, le … aux Etats-Unis par Ipsen sous la marque Iqirvo® …
-
Liquid Biopsy Could Detect Recurrence Prior to Scans in People with Colorectal Cancer
30 Apr 2025 16:45 GMT
… Jonathan Loree, MD, MS, a medical oncologist at BC Cancer and … for Amgen, Pfizer, Guardant Health, SAGA Diagnostics, Merck, Ipsen, and Novartis. Loree … or in-kind support from Ipsen, Guardant Health, SAGA Diagnostics, Bayer, and …
-
TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER
28 Apr 2025 23:55 GMT
… leading national partner, Revolution Medicines, and national sponsors Ipsen and AbbVie. For …
-
Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity
28 Apr 2025 01:22 GMT
… thoracic/head and neck medical oncology at MD Anderson.
Examining … , Axiom, Baptist Health Systems, Bayer, Beigene, Bicycle, BioCity Pharma, Bloom Burton, … , Haihe, Ideaya, ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce Karyopharm, KSQ, Kyowa, …
-
Regulatory tracker: AbbVie's Rinvoq scores 9th FDA nod, this time in GCA
02 Jan 2025 22:04 GMT
… Tazverik in China.
Epizyme, an Ipsen subsidiary through a 2022 merger … narrow indication given to the drug by the Medicines and Healthcare products Regulatory Agency (MHRA) and … six months of treatment.
Agios Pharmaceuticals’ Pyrukynd is up for an …
About
© 1995-2025